Additional file 2: of Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC

Table S1. Annotation of CpG sites in KDM gene family. (PDF 677 kb

Additional file 4: of Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC

Figure S2. Analysis work flow. Adenocarcinoma and squamous cell carcinoma samples from Harvard, Spain, Norway, and Sweden cohorts were used for the discovery phase of analysis. Data from The Cancer Genome Atlas (TCGA) were used for Validation. Ranger is a weighted version of random forest for controlling for the covariates including age, gender, smoking status, and histological stage. Variable importance score (VIS) was estimated for each CpG site and was ranked in descending order. CpG sites ranked in top 10% in both discovery and validation sets were selected for further evaluation by Cox regression. Multiple testing correction by false discovery rate (FDR) method was used if necessary. (PDF 357 kb

Additional file 1: of Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC

Figure S1. Quality control processes for DNA methylation chip data. Quality control measures and exclusion criteria as applied to Harvard, Spain, Norway, Sweden, and The Cancer Genome Atlas (TCGA) sample cohorts. (PDF 642 kb

Additional file 3: of Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC

Table S2. Distributions of CpG sites in KDM genes. (PDF 153 kb